Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

PhaseBio Pharmaceuticals, Inc. (PHAS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.9500-0.0400 (-2.01%)
At close: 04:00PM EST
1.9600 +0.01 (+0.51%)
After hours: 07:48PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.9900
Open1.9900
Bid1.9500 x 1100
Ask1.9500 x 1300
Day's Range1.8900 - 2.0110
52 Week Range1.8500 - 5.8300
Volume833,883
Avg. Volume657,188
Market Cap93.776M
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-3.0170
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PHAS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PhaseBio Pharmaceuticals, Inc.
    Analyst Report: United Therapeutics CorpUnited Therapeutics is a biotechnology company focused on the development and commercialization of therapeutic products for patients with cardiovascular conditions, cancer and infectious diseases. It has five approved products on the market and a strong new product pipeline. The company has roughly 950 employees and is a component of the S&P 400.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
Advertisement
Advertisement